Pharmacological treatment of fibromyalgia
- Pharmacy & Pharmacology International Journal
Diana Yisenia Pinzón Fajardo,1 Jose Julián Lopez Gutiérrez,1 Jorge Mario Camacho Carvajal2
PDF Full Text
Worldwide, fibromyalgia (FM) has increased its prevalence in recent years, becoming a public health problem. Despite the advances in research, this pathology remains uncertain, although several theories are known that try to explain its etiology and pathophysiology, the most accepted are focused on a multifactorial alteration, which causes a variation in different stages of the pain path both in the central and peripheral area. It lacks an objective method for its diagnosis and a therapeutic target, the result is an ineffective and insecure treatment, causing a negative impact on the quality of life of the sufferer and its environment, producing high costs in the health system. The main objective of this study is to describe the pharmacological management of FM, for which a descriptive, observational, retrospective study was carried out, based on the review of 75 medical records, in the integrated subnet of southern health services in Bogotá, finding prescriptions not in accordance with the European League against Rheumatism (EULAR) 2016 guide, given by the formulation of opioids, gabapentin, in monotherapy or dual therapy and triple with risky interactions, which are not indicated in this pathology due to their high risk, with Low profit and high costs. It is recommended to start with non-pharmacological management; When this is required, it should be performed individually based on the associated symptoms, not on pain, and also refrain from the formulation of combined treatments, since its long-term efficacy and safety are unknown.
fibromyalgia, pathophysiology, drug treatment, safety, costs